M. Liza Lindenberg, M.D.

Team Member of:
Liza Lindenberg, M.D. is a medical school graduate from the Uniformed Services University of the Health Sciences and was an Army physician for over 14 years prior to transferring to the U.S. Public Health Service and MIB in 2010. She is board certified in Nuclear Medicine and Family Medicine. Her research interests include PET tracers as biomarkers for therapeutic response in cancer treatments.
1) PET
Contact Info
Center for Cancer Research
National Cancer Institute
Bldg 10, Rm B3B402
Bethesda, MD 20892
Ph: 301-443-0604
liza.lindenberg@nih.gov
Selected Publications
-
Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging..Oncotarget. 6(6): 4496-504, 2015. [ Journal Article ]
-
Prospective Study Evaluating Na18F-Positron Emission Tomography/Computed Tomography (NaF-PET/CT) in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer.J Nucl Med. Jan 21: 2016. [ Journal Article ]
-
A pilot study of the value of 18F-fluoro-deoxy-thymidine PET/CT in predicting viable lymphoma in residual 18F-FDG avid masses after completion of therapy.Clin Nucl Med. 39 (10): 874-81, 2014. [ Journal Article ]
-
Does focal incidental 18F-FDG PET/CT uptake in the prostate have significance?.Abdom Imaging. 40 (8): 3222-9, 2015. [ Journal Article ]
-
PET/CT imaging of renal cell carcinoma with (18)F-VM4-037: a phase II pilot study.Abdom Radiol (NY). 41 (1): 109-18, 2016. [ Journal Article ]
Liza Lindenberg MD is a medical school graduate from the Uniformed Services University of the Health Sciences and was an Army physician for over 14 years prior to transferring to the US Public Health Service and MIP in 2010. She is board certified in Nuclear Medicine and Family Medicine. Her research interests include PET tracers as biomarkers for therapeutic response in cancer treatments.